CERDELGA
Drug
Genzyme Corporation
Total Payments
$79.7M
Transactions
3,218
Doctors
1,352
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $913,659 | 680 | 461 |
| 2023 | $15.4M | 585 | 384 |
| 2022 | $11.4M | 233 | 184 |
| 2021 | $16.5M | 241 | 186 |
| 2020 | $12.2M | 169 | 95 |
| 2019 | $8.4M | 733 | 239 |
| 2018 | $6.7M | 178 | 48 |
| 2017 | $8.2M | 399 | 42 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $75.5M | 33 | 94.7% |
| Unspecified | $2.5M | 171 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $681,625 | 229 | 0.9% |
| Consulting Fee | $590,709 | 194 | 0.7% |
| Travel and Lodging | $362,005 | 535 | 0.5% |
| Food and Beverage | $91,307 | 2,027 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $52,575 | 29 | 0.1% |
Payments by Type
General
$77.3M
3,047 transactions
Research
$2.5M
171 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ESC - Discovery of novel biomarkers to identify pre-symptomatic neurodegenerative Gaucher disease and inform clinical trials. | GENZYME CORPORATION | $1.1M | 0 |
| Eliglustat Tatrate Named Patient Program | SANOFI US SERVICES INC. | $798,123 | 1 |
| Validation Study for the US Rare EHR Screeing Algorithm | SANOFI US SERVICES INC. | $217,102 | 0 |
| Effect of Eliglustat on Bone disease in adult Gaucher Disease type 1 patients | SANOFI US SERVICES INC. | $109,662 | 0 |
| PK Metabolism-Healthy- Dose strengths proportionality-Oral | SANOFI US SERVICES INC. | $104,044 | 0 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease | GENZYME CORPORATION | $39,107 | 9 |
| ICGG Gaucher Registry | GENZYME CORPORATION | $17,490 | 4 |
| Effect of two different therapeutic interventions: SRT in comparison to ERT on immune aspects and bone involvement in Gaucher disease | GENZYME CORPORATION | $16,963 | 0 |
| Genzyme Pharma Ops / Medical Affairs_eliglustat CERDELGA | SANOFI US SERVICES INC. | $13,606 | 0 |
| Magnetic Resonance Spectroscopy Biomarkers in Type 3 Gaucher Disease | GENZYME CORPORATION | $12,591 | 0 |
| An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With N | SANOFI US SERVICES INC. | $9,395 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE) | GENZYME CORPORATION | $6,250 | 5 |
| GAUCHER REGISTRY | GENZYME CORPORATION | $3,590 | 4 |
| A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients | GENZYME CORPORATION | $2,500 | 2 |
| A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients | GENZYME CORPORATION | $2,275 | 1 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE) | GENZYME CORPORATION | $1,147 | 3 |
| An Open-label Fixed-sequence Study in Healthy Male and Female Subjects to Characterize the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of Genz-112638 Administered With and Withou | GENZYME CORPORATION | $144.00 | 1 |
| A Study of Eliglustat Tartrate Genz-112638 in Patients With Gaucher Disease | GENZYME CORPORATION | $93.33 | 1 |
Top Doctors Receiving Payments for CERDELGA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ann Arbor, MI | $77.9M | 155 |
| , MBBS PHD | Gastroenterology | New Haven, CT | $321,169 | 177 |
| , M.D | Specialist | Coral Springs, FL | $123,250 | 77 |
| , MD | Clinical Biochemical Genetics | Chicago, IL | $84,485 | 87 |
| , MD | Clinical Genetics (M.D.) | Little Rock, AR | $74,353 | 63 |
| , M.D | Neurology with Special Qualifications in Child Neurology | New York, NY | $72,997 | 47 |
| , M.D | Clinical Biochemical Genetics | Cincinnati, OH | $60,326 | 43 |
| , M.D., M.S | Clinical Genetics (M.D.) | New York, NY | $50,318 | 71 |
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $50,130 | 54 |
| , MD | Hematology & Oncology | Pembroke Pines, FL | $49,083 | 25 |
| , M.D | General Practice | Brooklyn, NY | $48,099 | 41 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $46,387 | 48 |
| Priya Kishnani | Pediatrics | Durham, NC | $46,119 | 33 |
| , M.D | Pediatric Hematology-Oncology | Dallas, TX | $41,418 | 22 |
| , MD | Internal Medicine | Beverly Hills, CA | $35,537 | 50 |
| , MD | Clinical Genetics (M.D.) | Greenville, SC | $35,155 | 30 |
| , O.D | Low Vision Rehabilitation | Schenectady, NY | $33,999 | 27 |
| , MD | Neurology | New York, NY | $33,313 | 26 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $31,500 | 46 |
| , RN, NP | Nurse Practitioner | Detroit, MI | $29,497 | 39 |
| , MD | Medical Oncology | Gainesville, FL | $27,532 | 12 |
| , MD PHD | Clinical Genetics (M.D.) | Cleveland, OH | $23,954 | 21 |
| , M.D | Clinical Genetics (M.D.) | New Orleans, LA | $21,927 | 20 |
| , MD | Hematology & Oncology | Weston, FL | $21,656 | 14 |
| , M.D | Internal Medicine | Detroit, MI | $19,134 | 14 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $70.7M
- Genzyme Corporation $7.6M
- SANOFI US SERVICES INC. $1.3M
- SANOFI-AVENTIS U.S. LLC $99,620
Product Information
- Type Drug
- Total Payments $79.7M
- Total Doctors 1,352
- Transactions 3,218
About CERDELGA
CERDELGA is a drug associated with $79.7M in payments to 1,352 healthcare providers, recorded across 3,218 transactions in the CMS Open Payments database. The primary manufacturer is Genzyme Corporation.
Payment data is available from 2017 to 2024. In 2024, $913,659 was paid across 680 transactions to 461 doctors.
The most common payment nature for CERDELGA is "Royalty or License" ($75.5M, 94.7% of total).
CERDELGA is associated with 18 research studies, including "ESC - Discovery of novel biomarkers to identify pre-symptomatic neurodegenerative Gaucher disease and inform clinical trials." ($1.1M).